Publicacións en colaboración con investigadores/as de Hospital Universitario 12 de Octubre (29)

2025

  1. Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score

    European heart journal, Vol. 46, Núm. 3, pp. 273-284

2024

  1. Colchicine in acute heart failure: Rationale and design of a randomized double-blind placebo-controlled trial (COLICA)

    European Journal of Heart Failure, Vol. 26, Núm. 9, pp. 1999-2007

  2. Colchicine in acutely decompensated heart failure: the COLICA trial

    European Heart Journal, Vol. 45, Núm. 45, pp. 4826-4836

2023

  1. Trends in cardiovascular care in the National Health System in Spain. Data from the RECALCAR project 2011-2020

    Revista Espanola de Cardiologia, Vol. 76, Núm. 7, pp. 519-530

2022

  1. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: Part 2-care pathways, treatment, and follow-up

    Cardiovascular Research, Vol. 118, Núm. 7, pp. 1618-1666

  2. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up

    European Heart Journal, Vol. 43, Núm. 11, pp. 1059-1103

  3. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis

    Cardiovascular research, Vol. 118, Núm. 6, pp. 1385-1412

  4. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis

    European Heart Journal, Vol. 43, Núm. 11, pp. 1033-1058

  5. Rapid Molecular Diagnosis of Genetically Inherited Neuromuscular Disorders Using Next-Generation Sequencing Technologies

    Journal of Clinical Medicine, Vol. 11, Núm. 10

  6. Renal Function Impact in the Prognostic Value of Galectin-3 in Acute Heart Failure

    Frontiers in Cardiovascular Medicine, Vol. 9

2021

  1. A 3-Biomarker 2-Point-Based Risk Stratification Strategy in Acute Heart Failure

    Frontiers in Physiology, Vol. 12

  2. Ischemic etiology and prognosis in men and women with acute heart failure

    Journal of Clinical Medicine, Vol. 10, Núm. 8

  3. Persistent pulmonary hypertension in corrected valvular heart disease: Hemodynamic insights and long-term survival

    Journal of the American Heart Association, Vol. 10, Núm. 2, pp. 1-21

  4. Prognostic impact of hyponatraemia and hypernatraemia at admission and discharge in heart failure patients with preserved, mid-range and reduced ejection fraction

    Internal Medicine Journal, Vol. 51, Núm. 6, pp. 930-938

2020

  1. Prevalence, clinical profile and prognostic implications of interatrial block in patients admitted for heart failure

    REC: CardioClinics, Vol. 55, Núm. 3, pp. 155-164

2019

  1. Discharge treatment with angiotensin-converting enzyme inhibitor/angiotensin receptor blocker after a heart failure hospitalisation is associated with a better prognosis irrespective of left ventricular ejection fraction

    Internal Medicine Journal, Vol. 49, Núm. 12, pp. 1505-1513

  2. Impact of acetate- or citrate-acidified bicarbonate dialysate on ex vivo aorta wall calcification

    Scientific Reports, Vol. 9, Núm. 1

  3. Patient-Associated Predictors of 15- and 30-Day Readmission After Hospitalization for Acute Heart Failure

    Current Heart Failure Reports, Vol. 16, Núm. 6, pp. 304-314

2018

  1. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: A multicenter, double-blind, randomized clinical trial

    European Heart Journal, Vol. 39, Núm. 15, pp. 1255-1264

2017

  1. Efficacy of laronidase therapy in patients with mucopolysaccharidosis type I who initiated enzyme replacement therapy in adult age. A systematic review and meta-analysis

    Molecular Genetics and Metabolism, Vol. 121, Núm. 2, pp. 138-149